Informações de Altimmune Inc

Mais detalhes de Altimmune Inc Empresa

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.



Código da empresaALT

Nome da EmpresaAltimmune Inc

Data de listagemOct 06, 2005

CEODr. Vipin K. Garg, Ph.D.

Número de funcionários59

Tipo de títulosOrdinary Share

Fim do ano fiscalOct 06

Endereço910 Clopper Road

CidadeGAITHERSBURG

Bolsa de valoresNASDAQ Global Market Consolidated

PaísUnited States of America

Código postal20878-1361

Telefone12406541450

Sitehttps://altimmune.com/

Código da empresaALT

Data de listagemOct 06, 2005

CEODr. Vipin K. Garg, Ph.D.

Executivos da empresa Altimmune Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Vipin K. Garg, Ph.D.

President, Chief Executive Officer, Director

355.08K

--

Mr. Raymond M. (Ray) Jordt

Chief Business Officer

36.27K

+3.92%

Dr. Mitchel B. (Mitch) Sayare, Ph.D.

Independent Director

26.36K

--

Mr. Gregory L. (Greg) Weaver

Chief Financial Officer

10.00K

--

Brig. Gen. (Retd.) Klaus O. Schafer, M.D.

Independent Director

9.18K

--

Dr. Catherine Angell Sohn, Pharm.D.

Independent Director

1.00K

--

Ms. Linda M. Richardson

Chief Commercial Officer

--

Mr. Philip L. Hodges

Independent Director

--

Mr. Jerome Benedict (Jerry) Durso

Chairman of the Board

--

Dr. M. Scot Roberts, Ph.D.

Chief Scientific Officer

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Vipin K. Garg, Ph.D.

President, Chief Executive Officer, Director

355.08K

--

Mr. Raymond M. (Ray) Jordt

Chief Business Officer

36.27K

+3.92%

Dr. Mitchel B. (Mitch) Sayare, Ph.D.

Independent Director

26.36K

--

Mr. Gregory L. (Greg) Weaver

Chief Financial Officer

10.00K

--

Brig. Gen. (Retd.) Klaus O. Schafer, M.D.

Independent Director

9.18K

--

Dr. Catherine Angell Sohn, Pharm.D.

Independent Director

1.00K

--

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: ter, 4 de nov

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

6.11%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

2.64%

Tang Capital Management, LLC

2.64%

Geode Capital Management, L.L.C.

1.86%

Outro

81.23%

Investidores

Proporção

The Vanguard Group, Inc.

6.11%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

2.64%

Tang Capital Management, LLC

2.64%

Geode Capital Management, L.L.C.

1.86%

Outro

81.23%

Tipos de investidores

Investidores

Proporção

Investment Advisor

20.68%

Investment Advisor/Hedge Fund

9.49%

Hedge Fund

7.78%

Research Firm

3.16%

Individual Investor

0.73%

Bank and Trust

0.38%

Pension Fund

0.05%

Insurance Company

0.03%

Outro

57.70%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

405

38.06M

36.57%

-11.64M

2025Q2

413

40.03M

49.36%

-12.37M

2025Q1

433

39.51M

48.72%

-15.43M

2024Q4

439

41.91M

54.50%

-15.25M

2024Q3

440

40.83M

57.43%

-21.59M

2024Q2

436

43.67M

61.47%

-20.29M

2024Q1

418

45.76M

64.68%

-11.45M

2023Q4

387

34.44M

49.06%

-14.90M

2023Q3

368

31.34M

59.36%

-25.59M

2023Q2

362

36.16M

68.78%

-25.80M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

5.17M

5.85%

+772.36K

+17.57%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.75M

6.52%

+223.90K

+4.05%

Jun 30, 2025

State Street Investment Management (US)

2.75M

3.12%

-637.93K

-18.81%

Jun 30, 2025

Tang Capital Management, LLC

2.75M

3.12%

--

Jun 30, 2025

Geode Capital Management, L.L.C.

1.93M

2.19%

+229.00K

+13.42%

Jun 30, 2025

Susquehanna International Group, LLP

1.62M

1.84%

+543.68K

+50.53%

Jun 30, 2025

Knoll Capital Management, LLC

1.12M

1.27%

--

Jun 30, 2025

Caption Management, LLC

980.78K

1.11%

+941.92K

+2423.62%

Jun 30, 2025

BofA Global Research (US)

716.02K

0.81%

+435.47K

+155.22%

Jun 30, 2025

UBS Financial Services, Inc.

633.56K

0.72%

-94.60K

-12.99%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

Invesco NASDAQ Future Gen 200 ETF

0.48%

Virtus LifeSci Biotech Clinical Trials ETF

0.38%

SPDR S&P Biotech ETF

0.15%

Direxion Daily S&P Biotech Bull 3X Shares

0.08%

Fidelity Enhanced Small Cap ETF

0.06%

iShares Micro-Cap ETF

0.06%

iShares Biotechnology ETF

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

ProShares Ultra Nasdaq Biotechnology

0.03%

iShares Russell 2000 Growth ETF

0.02%

Ver Mais

Invesco NASDAQ Future Gen 200 ETF

Proporção0.48%

Virtus LifeSci Biotech Clinical Trials ETF

Proporção0.38%

SPDR S&P Biotech ETF

Proporção0.15%

Direxion Daily S&P Biotech Bull 3X Shares

Proporção0.08%

Fidelity Enhanced Small Cap ETF

Proporção0.06%

iShares Micro-Cap ETF

Proporção0.06%

iShares Biotechnology ETF

Proporção0.03%

Invesco Nasdaq Biotechnology ETF

Proporção0.03%

ProShares Ultra Nasdaq Biotechnology

Proporção0.03%

iShares Russell 2000 Growth ETF

Proporção0.02%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados